Large interest in the newly launched clinical trial for 2cureX’s IndiTreat™ test
2cureX AB (“2cureX”) and its clinical partners have launched a clinical trial where IndiTreat ™ supports the oncologist in providing the most effective treatment for patients with stage IV colorectal cancer. IndiTreat™ generates micro-tumors from the patient’s cancer tissue and challenges these micro-tumors with a large panel of standard and off-label treatments. The treatment that stops the growth and kills the micro-tumors from the individual patient is then offered by the oncologist to the patient.
The clinical trial was launched in Denmark end of October and will in 2018 be extended to Germany (University Medical Center Hamburg-Eppendorf) and the United Kingdom (Queen Elisabeth Hospital Birmingham). The study is an Investigator-Initiated clinical trial with Consultant, Associate Professor Lars Henrik Jensen (Department of Oncology, Vejle Hospital) as the principal investigator.
“There is an urgent need for methods to predict clinical benefit from different drugs for the individual patient” states Lars Henrik Jensen, and he continues “The idea of personalized medicine, i.e. treatment tailored to an individual patient based on a biomarker, has largely failed in colorectal cancer. The new method of using growing micro-tumors to test many different drugs is very attractive to us and to our patients. It is therefore a pleasure for us to be sponsor of this multinational trial.” Lars Henrik Jensen concludes: “During this first month of patient recruitment, we have experienced a huge interest from patients to participate which is a prerequisite for a successful trial.”
IndiTreat™ has been developed by 2cureX in its laboratory facilities at hospitals in Copenhagen and in Hamburg. It is the expectation by 2cureX and its clinical partners that IndiTreat™ will become a standard tool for the oncologist to choose the right treatment for the individual patient.
“Successful launch of this clinical validation trial is a major milestone reached for 2cureX” states the CEO of 2cureX, Ole Thastrup. He continues: “It is a pleasure to see that the trial has come off to a good start with a significant interest from patients. This combined with the fact that our hospital partners in Germany and United Kingdom will be ready to recruit patients as planned in 2018 makes me optimistic that we can keep our time-plan for market-launch of the first IndiTreat™ product in 2020”.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
2cureX has developed IndiTreat ™ (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat™ is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).